ClinicalTrials.gg
CompletedNCT02446418Updated Jan 14, 2019Results posted

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

A Phase 3 interventional study of Fluticasone Furoate and Vilanterol in Asthma, sponsored by GlaxoSmithKline. Completed at 93 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-01-14.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
423
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
12th of 40
423 · median 102
Started
2015
with 2 others
Phase 3
14 of 40
none open now
Registered
27th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 12th largest by enrollment, is one of 3 that started in 2015, is one of 14 in phase 3, and was the 27th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

The combination of FF, an ICS and VI, an orally inhaled LABA has been developed as a once-daily combination therapy for the long-term maintenance treatment of asthma in adults and children >=12 years of age. Pivotal phase III studies have demonstrated the safety and efficacy of FF/VI in asthma. However, it is increasingly acknowledged that randomised clinical trials tend to be highly controlled and enrol a more highly selected subject population than is expected to be prescribed the medication post-approval. There is a need for data in a more representative population in close to a 'real life' conditions, where physicians have the ability to choose the best treatment in their view for any individual subject and adapt treatments to subjects' characteristics and response. This multi-center, open-label, randomized, parallel group study will evaluate the efficacy and safety of FF/VI compared with two usual ICS/LABA fixed combination (fluticasone propionate/salmeterol [FP/S] or budesonide/formoterol [BUD/F]) in subjects with persistent asthma, in a "close to real life" settings. FF/VI will be administered once-daily (QD) via ELLIPTA dry powder inhaler (DPI) and FP/S or BUD/F will be administered twice daily (BID) via DISKUS™ and TURBUHALER™ DPI respectively. ELLIPTA is a new powder inhaler designed to be easy to use. The total duration of subject participation will be approximately 6 months (24 weeks). ELLIPTA and DISKUS are registered trademarks of the GSK group of companies. TURBUHALER is a registered trademark of AstraZeneca.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • dry powder inahler
  • vilanerol
  • efficacy
  • safety
  • fluticasone furoate
  • quality of life
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.
  • Gender and Age: Male or female subjects aged >=18 and \<=75years of age at Screening visit.

Female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies:

Non- defined as: Pre-menopausal females with one of the following - Documented tubal ligation; Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy; Documented Bilateral Oophorectomy. defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause [refer to laboratory reference ranges for confirmatory levels]); Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.

Reproductive potential and agrees to follow one of the options listed below in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study medication and until Week 24.

GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in FRP:

This list does not apply to FRP with same sex partners, when this is their preferred and usual lifestyle or for subjects who are and will continue to be abstinent from penile-vaginal intercourse on a long term and persistent basis: Contraceptive subdermal implant that meets the Standard Operating Procedure (SOP) effectiveness criteria including a \<1percent rate of failure per year, as stated in the product label; Intrauterine device or intrauterine system that meets the SOP effectiveness criteria including a \<1 percent rate of failure per year, as stated in the product label; Oral Contraceptive, either combined or progestogen alone; Injectable progestogen; Contraceptive vaginal ring; Percutaneous contraceptive patches; Male partner sterilization with documentation of azoospermia prior to the female subject's entry into the study, and this male is the sole partner for that subject; Male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository); These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.

  • Type of subject: Subjects with documented physician's diagnosis of asthma >=1 year, unsatisfactorily controlled asthma (ACT \<20 at Screening and Randomisation visit) treated by ICS alone and intended to be treated by ICS/LABA maintenance therapy; France Only: A subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a Social Security category.
  • Current Asthma Therapy: All subjects must be prescribed maintenance therapy and receiving ICS alone without LABA for at least 4 weeks prior to Randomisation visit; Other background asthma medication such as anti-leukotrienes or theophylline is permitted as an alternative to ICS alone, if initiated at least 4 weeks prior to screening visit.
  • Subject questionnaires Subjects must be able to complete the questionnaires themselves.

Exclusion criteria

Exclusion Criteria:

  • History of Life-threatening asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 6 months before Screening and Randomisation visit.
  • Subjects having a severe and unstable asthma, with ACT score \< 15 at Visit 1 and at Visit 2, and/or a history of repeated severe exacerbations (3/year) and/or a severe exacerbation in the previous 6 weeks before Visit 1 and Visit 2.
  • (COPD) Respiratory Disease: A subject must not have current evidence or diagnosis of chronic obstructive pulmonary disease at Screening visit.
  • Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at screening [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)].
  • Other diseases/abnormalities: Subjects with historical or current evidence of uncontrolled or disease at Screening and Randomisation visit. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • Subjects with a history of adverse reaction including immediate or delayed to any intranasal, inhaled, or systemic and LABA therapy and to components of the inhalation powder (e.g., lactose, magnesium stearate) at Screening and Randomisation visit. In addition, subjects with a history of severe milk protein allergy that, in the opinion of the Investigator, contraindicates the subject's participation will also be excluded.
  • Medications: A subject must not have used any investigational drug within 30 days prior to Randomisation visit or within five half-lives (t½) of the prior investigational study (whichever is longer of the two), (if unsure discuss with the medical monitor prior to screening).
  • Chronic user of systemic corticosteroids: A subject who, in the opinion of the Investigator, is considered to be a chronic user of systemic corticosteroids for respiratory or other indications (if unsure discuss with the medical monitor prior to screening) at Screening visit.
  • Subjects treated by the monoclonal antibody omalizumab or mepolizumab at Visit 1. Treatment with omalizumab or mepolizumab is not allowed during the study.
  • Subjects involved in other clinical trials at Screening visit.
  • Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study.
  • Subjects who plan to move away from the geographical area where the study is being conducted during the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
423 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate/Vilanterol

    Subjects will receive FF/VI 92 micrograms (mcg)/22 mcg or FF/VI 184 mcg/22 mcg as decided by the investigator QD via ELLIPTA DPI for 24 weeks.

    Drug: Fluticasone Furoate · Drug: Vilanterol

  • Active comparator
    FP/S OR BUD/F

    Subjects will receive FP/S (250 mcg/50 mcg or 500 mcg/50mcg) twice daily via DISKUS or BUD /F (200 mcg/6mcg or 400 mcg/12mcg one or two inhalations) twice daily via TURBUHALER DPI as decided by the investigator for 24 weeks.

    Drug: Fluticasone propionate · Drug: Salmeterol · Drug: Budesonide · Drug: Formoterol Fumarate

Interventions

  • FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI

  • Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI

  • FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI

  • Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI

  • Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI

  • Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Asthma Control Test (ACT) Total Score at Week 12

    The ACT is a validated self-completed questionnaire consisting of 5 questions that evaluate asthma control during the past 4 weeks on a 5-point categorical scale. Total scores are calculated from the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 19 suggests that the participant's asthma is unlikely to be well controlled, whilst a score of 20 to 25 suggests that the participant's asthma is likely to be well controlled. Baseline value was the last assessment prior to randomization (Day 0). Change from Baseline was post-dose visit value minus the Baseline value. Least square mean change is presented.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in ACT Total Score at Week 24

    The ACT is a validated self-completed questionnaire consisting of 5 questions that evaluate asthma control on a 5-point categorical scale. Total scores are calculated from the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 19 suggests that the participant's asthma is unlikely to be well controlled, whilst a score of 20 to 25 suggests that the participant's asthma is likely to be well controlled. Baseline value was the last assessment prior to randomization (Day 0). Change from Baseline was post-dose visit value minus the Baseline value. Least square mean change is presented.

    Time frame: Baseline and Week 24

  2. Percentage of Participants With Correct Use of Device, Defined as Not Making Any Critical or Non-critical Errors, at Week 12, and at Week 24 Independently of the Use at Week 12

    Participants were asked to read the appropriate package insert for their prescribed inhaler and then the investigator (or suitably qualified designee) demonstrated the proper use of the inhaler. The participant was then asked to self-administer their first dose of study treatment under the supervision of the investigator and any critical and non-critical errors were recorded. Individual instruments for assessing correct inhaler use were provided for each of the three devices used in this study.

    Time frame: Week 12 and Week 24

07

Results

Posted Jan 14, 2019

Participant flow

A total of 439 participants with persistent asthma were screened. The study was conducted at 63 centers in 2 countries: 43 in France and 20 in Germany from 09 July 2015 to 20 July 2017. Age value being reported for all participants is an approximate age accurate to within + or -1 year.

Participant flow — Overall Study
MilestoneUsual ICS/LABAFF/VI
Started210210
Completed192194
Not completed1816
Withdrew: Adverse event48
Withdrew: Physician decision51
Withdrew: Withdrawal by subject33
Withdrew: Lost to follow-up22
Withdrew: Protocol violation12
Withdrew: Lack of efficacy20
Withdrew: Protocol defined stopping criteria reach10

Outcome measures

PrimaryChange From Baseline in Asthma Control Test (ACT) Total Score at Week 12

The ACT is a validated self-completed questionnaire consisting of 5 questions that evaluate asthma control during the past 4 weeks on a 5-point categorical scale. Total scores are calculated from the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 19 suggests that the participant's asthma is unlikely to be well controlled, whilst a score of 20 to 25 suggests that the participant's asthma is likely to be well controlled. Baseline value was the last assessment prior to randomization (Day 0). Change from Baseline was post-dose visit value minus the Baseline value. Least square mean change is presented.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Scores on a Scale
Change From Baseline in Asthma Control Test (ACT) Total Score at Week 12
Scores on a ScaleUsual ICS/LABAFF/VI
Change From Baseline in Asthma Control Test (ACT) Total Score at Week 122.8 ± 0.263.6 ± 0.26
Statistical analysis
  • Usual ICS/LABA vs FF/VI · Mixed model repeated measures (MMRM) · p = 0.033 · Mean difference (net): 0.8 · 95% CI 0.1 to 1.5
SecondaryChange From Baseline in ACT Total Score at Week 24

The ACT is a validated self-completed questionnaire consisting of 5 questions that evaluate asthma control on a 5-point categorical scale. Total scores are calculated from the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 19 suggests that the participant's asthma is unlikely to be well controlled, whilst a score of 20 to 25 suggests that the participant's asthma is likely to be well controlled. Baseline value was the last assessment prior to randomization (Day 0). Change from Baseline was post-dose visit value minus the Baseline value. Least square mean change is presented.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Scores on a Scale
Change From Baseline in ACT Total Score at Week 24
Scores on a ScaleUsual ICS/LABAFF/VI
Change From Baseline in ACT Total Score at Week 243.6 ± 0.254.0 ± 0.25
Statistical analysis
  • Usual ICS/LABA vs FF/VI · Mixed model repeated measures (MMRM) · p = 0.224 · Mean difference (net): 0.4 · 95% CI -0.3 to 1.1
SecondaryPercentage of Participants With Correct Use of Device, Defined as Not Making Any Critical or Non-critical Errors, at Week 12, and at Week 24 Independently of the Use at Week 12

Participants were asked to read the appropriate package insert for their prescribed inhaler and then the investigator (or suitably qualified designee) demonstrated the proper use of the inhaler. The participant was then asked to self-administer their first dose of study treatment under the supervision of the investigator and any critical and non-critical errors were recorded. Individual instruments for assessing correct inhaler use were provided for each of the three devices used in this study.

Time frame:
Week 12 and Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Correct Use of Device, Defined as Not Making Any Critical or Non-critical Errors, at Week 12, and at Week 24 Independently of the Use at Week 12
Percentage of participantsUsual ICS/LABAFF/VI
Week 12; n= 195, 1979394
Week 24; n= 191, 1929697
Statistical analysis
  • Usual ICS/LABA vs FF/VI · Regression, Logistic · p = 0.820 · Adjusted odds ratio: 1.11 · 95% CI 0.47 to 2.62
  • Usual ICS/LABA vs FF/VI · Regression, Logistic · p = 0.566 · Adjusted odds ratio: 1.41 · 95% CI 0.43 to 4.60

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse drug reactions were collected from start of study treatment up to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Usual ICS/LABA0/210 (0%)4/210 (1.9%)0/210 (0%)
FF/VI0/209 (0%)3/209 (1.4%)0/209 (0%)
Most frequent serious events
Most frequent serious events
EventUsual ICS/LABAFF/VI
LabyrinthitisInfections and infestations0/2101/209
Ovarian abscessInfections and infestations0/2101/209
Adnexa uteri painReproductive system and breast disorders0/2101/209
Varicose vein rupturedVascular disorders0/2101/209
Chronic sinusitisInfections and infestations1/2100/209
ErysipelasInfections and infestations1/2100/209
Abdominal painGastrointestinal disorders1/2100/209
EpilepsyNervous system disorders1/2100/209
Skin ulcerSkin and subcutaneous tissue disorders1/2100/209

Baseline characteristics

ITT Population comprised of all randomized participants who received at least one dose of the prescription of study medication (either FF/VI or usual ICS/LABA).

Age, Continuous
Age, Continuous(Years)Usual ICS/LABAFF/VITotal
Mean47.5 ± 14.9949.3 ± 14.6748.4 ± 14.84
Sex: Female, Male
Sex: Female, Male(Participants)Usual ICS/LABAFF/VITotal
Female124145269
Male8665151
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Usual ICS/LABAFF/VITotal
African American/African Heritage347
Asian - Central/South Asian Heritage011
Asian - East Asian Heritage202
Asian - South East Asian Heritage011
Native Hawaiian Or Other Pacific Islander112
White - Arabic/North African Heritage8614
White - White/Caucasian/European Heritage196196392
Mixed White Race011
08

Study locations

93 sites
  • GSK Investigational Site
    Amiens, 80090, France
  • GSK Investigational Site
    Angers, 49000, France
  • GSK Investigational Site
    Avelin, 59710, France
  • GSK Investigational Site
    Bassussarry, 64200, France
  • GSK Investigational Site
    Beauzelle, 31700, France
  • GSK Investigational Site
    Bersee, 59235, France
  • GSK Investigational Site
    Beziers, 34500, France
  • GSK Investigational Site
    Biarritz, 64200, France
  • GSK Investigational Site
    Bourg Des Comptes, 35890, France
  • GSK Investigational Site
    Broglie, 27270, France
  • GSK Investigational Site
    Bruay-la-Buissière, 62700, France
  • GSK Investigational Site
    Bécon les Granits, 49370, France
  • GSK Investigational Site
    Caen, 14000, France
  • GSK Investigational Site
    Cannes Cedex, 06614, France
  • GSK Investigational Site
    Carbon-Blanc, 33560, France
  • GSK Investigational Site
    Chatellerault, 86100, France
  • GSK Investigational Site
    Colombey-les-Belles, 54170, France
  • GSK Investigational Site
    Coulounieix-Chamiers, 24660, France
  • GSK Investigational Site
    Cournonterral, 34660, France
  • GSK Investigational Site
    Dessenheim, 68600, France
  • GSK Investigational Site
    Dijon, 21000, France
  • GSK Investigational Site
    Dinard, 35800, France
  • GSK Investigational Site
    Donges, 44480, France
  • GSK Investigational Site
    Ermont cedex, 95124, France
  • GSK Investigational Site
    Fleville Devant Nancy, 54710, France
  • GSK Investigational Site
    Gemenos, 13420, France
  • GSK Investigational Site
    Gondreville, 54840, France
  • GSK Investigational Site
    Grenay, 62160, France
  • GSK Investigational Site
    Guesnain, 59287, France
  • GSK Investigational Site
    Hatten, 67690, France
  • GSK Investigational Site
    Hinx, 40180, France
  • GSK Investigational Site
    La Bouexiere, 35340, France
  • GSK Investigational Site
    La Fôret Sur Sèvres, 79380, France
  • GSK Investigational Site
    La Riche, 37520, France
  • GSK Investigational Site
    Lambersart, 59130, France
  • GSK Investigational Site
    Laval, 53000, France
  • GSK Investigational Site
    Le Blanc-Mesnil, 93150, France
  • GSK Investigational Site
    Limoges, 87000, France
  • GSK Investigational Site
    Marseille cedex 03, 13331, France
  • GSK Investigational Site
    Metz-Tessy, 74370, France
  • GSK Investigational Site
    Montauban cedex, 82017, France
  • GSK Investigational Site
    Montpellier Cedex 5, 34295, France
  • GSK Investigational Site
    Montpellier, 34070, France
  • GSK Investigational Site
    Murs-Erigne, 49610, France
  • GSK Investigational Site
    Nancy, 54000, France
  • GSK Investigational Site
    Nantes, 44200, France
  • GSK Investigational Site
    Nantes, 44300, France
  • GSK Investigational Site
    Narbonne, 11100, France
  • GSK Investigational Site
    Nice, 06000, France
  • GSK Investigational Site
    Obernai, 67210, France
  • GSK Investigational Site
    Paris, 75020, France
  • GSK Investigational Site
    Perpignan, 66000, France
  • GSK Investigational Site
    Rosiers-d'Egletons, 19300, France
  • GSK Investigational Site
    Rouen, 76000, France
  • GSK Investigational Site
    Royaumeix, 54200, France
  • GSK Investigational Site
    Saint Etienne, 42100, France
  • GSK Investigational Site
    Saint Ouen la Rouerie, 35460, France
  • GSK Investigational Site
    Saint-Etienne, 42000, France
  • GSK Investigational Site
    Scorbe Clairvaux, 86140, France
  • GSK Investigational Site
    Segré, 49500, France
  • GSK Investigational Site
    Soulac-sur-Mer, 33780, France
  • GSK Investigational Site
    Strasbourg, 67000, France
  • GSK Investigational Site
    Thouars, 79100, France
  • GSK Investigational Site
    Toulon, 83000, France
  • GSK Investigational Site
    Toulouse cedex 4, 31077, France
  • GSK Investigational Site
    Toulouse, 31300, France
  • GSK Investigational Site
    Toul, 54200, France
  • GSK Investigational Site
    Verzy, 51380, France
  • GSK Investigational Site
    Vieux Condé, 59690, France
  • GSK Investigational Site
    Villejuif, 94800, France
  • GSK Investigational Site
    Wattrelos, 59150, France
  • GSK Investigational Site
    Witry les Reims, 51420, France
  • GSK Investigational Site
    Muenchen, Bayern 80339, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81241, Germany
  • GSK Investigational Site
    Wallerfing, Bayern 94574, Germany
  • GSK Investigational Site
    Potsdam, Brandenburg 14469, Germany
  • GSK Investigational Site
    Dortmund, Nordrhein-Westfalen 44263, Germany
  • GSK Investigational Site
    Rheine, Nordrhein-Westfalen 48431, Germany
  • GSK Investigational Site
    Teuchern, Sachsen-Anhalt 6682, Germany
  • GSK Investigational Site
    Delitzsch, Sachsen 04509, Germany
  • GSK Investigational Site
    Leipzg, Sachsen 04109, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04103, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04207, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04275, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04357, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Schmoelln, Thueringen 04626, Germany
  • GSK Investigational Site
    Berlin, 10119, Germany
  • GSK Investigational Site
    Berlin, 10717, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 13156, Germany
  • GSK Investigational Site
    Berlin, 14059, Germany
  • GSK Investigational Site
    Magdeburg, 39120, Germany
09

References and documents

Publications

  • Devillier P, Humbert M, Boye A, Zachgo W, Jacques L, Nunn C, West S, Nicholls A, Antoun Z, Spinu L, Grouin JM. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting beta2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial. Respir Med. 2018 Aug;141:111-120. doi: 10.1016/j.rmed.2018.06.009. Epub 2018 Jun 9. PubMed 30053956 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Jul 2017, 24 months.

Results were first posted in Jan 2019, 1 year 5 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 24 months is close to that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2015
First posted
May 18, 2015
StartActual
Jul 9, 2015
Primary completionActual
Jul 20, 2017
CompletionActual
Jul 20, 2017
Results first posted
Jan 14, 2019
Last update
Jan 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02446418
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 18, 2015
Start date
Jul 9, 2015
Primary completion
Jul 20, 2017
Completion
Jul 20, 2017
Results posted
Jan 14, 2019
Last update
Jan 14, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion